PhaseBio is evaluating multiple preclinical candidates based on the ELP biopolymer technology, focusing on two major areas:

  • Proteins and peptides for high unmet medical needs in orphan indications that can benefit from our technology platform and half-life extension
  • Scientifically or clinically validated proteins and peptides in order to create fast follower/improved products

The pipeline candidates will be disclosed following selection for IND-enabling studies.